Novo Nordisk A/S produced significant gains in sales and earnings in the first nine months of 2011, mainly as a result of booming sales of Victoza (liraglutide) which was approved in Europe in July 2009 and in the US in January 2010. ---Subscribe to MedNous to access this article--- Company News
